



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 544976084 US, in an envelope addressed to: MS RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 16, 2005

Signature:

Georgina Matos
Georgina Matos

PATENT
Docket No. 544582000200
Client Reference No. WEAN-423011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anton WELLSTEIN

Serial No.: 09/880,097

Filing Date: June 14, 2001

For: PLEIOTROPHIN GROWTH FACTOR
RECEPTOR FOR THE TREATMENT OF
PROLIFERATIVE, VASCULAR AND
NEUROLOGICAL DISORDERS.

Examiner: C. Nichols

Group Art Unit: 1647

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

03/23/2005 SSESHE1 00000008 031952 09880097

03 FC:1806 180.00 DA

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

Application Serial No. 09/880,097

PATENT
Docket No. 544582000200
Client Reference No. WEAN-423011

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **544582000200**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 16, 2005

Respectfully submitted,

By Jill A. Jacobson
Jill A. Jacobson
Registration No. 40,030 for
Debra J. Glaister
Registration No.: 33,888
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, CA 94304-1018
(650)813-5725



Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/880,097
		Filing Date	June 14, 2001
		First Named Inventor	Anton WELLSTEIN
		Art Unit	1647
		Examiner Name	C: Nichols
		Attorney Docket Number	544582000200
Sheet	1	of	3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-6,696,548-B2	02-24-2004	Morris et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	2.	WO-01/96394-A2, A3	12-20-2001	Georgetown University Medical Center		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3.	Albertoni, M. et al. (January 22, 1998). "Genetic Instability Leads to Loss of Both p53 Alleles in a Human Glioblastoma," <i>Oncogene</i> 16(3):321-326.	
	4.	Bashkin, P. et al. (February 21, 1989). "Basic Fibroblast Growth Factor Binds to Subendothelial Extracellular Matrix and Is Released by Heparitinase and Heparin-Like Molecules," <i>Biochemistry</i> 28(4):1737-1743.	
	5.	Basilico, C. et al. (1992). "The FGF Family of Growth Factors and Oncogenes," <i>In Advances in Cancer Research</i> Academic Press, Inc.: San Diego, CA 59:115-165.	
	6.	Bowers, D.C. et al. (August 1, 2000). "Scatter Factor/Hepatocyte Growth Factor Protects Against Cytotoxic Death in Human Glioblastoma via Phosphatidylinositol 3-Kinase- and AKT-dependent Pathways," <i>Cancer Res.</i> 60(15):4277-4283.	
	7.	Buczek-Thomas, J.A. et al. (1999). "Elastase-Mediated Release of Heparan Sulfate Proteoglycans from Pulmonary Fibroblast Cultures. A Mechanism for Basic Fibroblast Growth Factor (bFGF) Release and Attenuation of bFGF Binding Following Elastase-Induced Injury," <i>J. Biol. Chem.</i> 274:25167-25172.	
	8.	Chauhan, A.K. et al. (January 1993). "Pleiotrophin Transforms NIH 3T3 Cells and Induces Tumors in Nude Mice," <i>Proc. Natl. Acad. Sci. USA</i> 90:679-682.	
	9.	Choudhuri, R. et al. (May 1, 1997). "An Angiogenic Role for the Neurokinin Midkine and Pleiotrophin in Tumorigenesis," <i>Cancer Res.</i> 57(9):1814-1819.	
	10.	Czubayko, F. et al. (August 19, 1994). "Ribozyme-Targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth," <i>J. Biol. Chem.</i> 269(33):21358-21363.	
	11.	Czubayko, F. et al. (November 11, 1994). "Tumor Growth and Angiogenesis Induced by a Secreted Binding Protein for Fibroblast Growth Factors," <i>J. Biol. Chem.</i> 269(45):28243-28248.	
	12.	Czubayko, F. et al. (December 1996). "Melanoma Angiogenesis and Metastasis Modulated by Ribozyme Targeting of the Secreted Growth Factor Pleiotrophin," <i>Proc. Natl. Acad. Sci. USA</i> 93:14753-14758.	
	13.	Czubayko, F. et al. (1997). "Adenovirus-Mediated Transduction of Ribozymes Abrogates HER-2/neu and Pleiotrophin Expression and Inhibits Tumor Cell Proliferation," <i>Gene Therapy</i> 4:943-949.	

Examiner Signature	Date Considered
--------------------	-----------------



Substitute for form 1449/PTO		Complete if Known	
		Application Number	09/880,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	June 14, 2001
		First Named Inventor	Anton WELLSTEIN
		Art Unit	1647
		Examiner Name	C. Nichols
		Attorney Docket Number	544582000200
		Sheet	2

14.	Czubayko, F. et al. (October 1997). "A Secreted FGF-Binding Protein Can Serve as the Angiogenic Switch in Human Cancer," <i>Nat. Med.</i> 3(10):1137-1140.
15.	Dove, A. (March 1999). "Proteomics: Translating Genomics into Products?" <i>Nat. Biotechnol.</i> 17:233-236.
16.	Fang, W. et al. (December 25, 1992). "Pleiotrophin Stimulates Fibroblasts and Endothelial and Epithelial Cells and Is Expressed in Human Cancer," <i>J. Biol. Chem.</i> 267(36):25889-25897.
17.	Furnari, F.B. et al. (November 1997). "Growth Suppression of Glioma Cells by PTEN Requires a Functional Phosphatase Catalytic Domain," <i>Proc. Natl. Acad. Sci. USA</i> 94:12479-12484.
18.	GenBank Accession No. U66559, created on February 24, 1997, located at < http://www.ncbi.nlm.nih.gov > last visited on March 3, 2005, three pages.
19.	Hanahan, D. et al. (January 7, 2000). "The Hallmarks of Cancer," <i>Cell</i> 100:57-70.
20.	Holland, E.C. (June 6, 2000). "Glioblastoma Multiforme: The Terminator," <i>Proc. Natl. Acad. Sci. USA</i> 97(12):6242-6244.
21.	Holland, E.C. et al. (May 2000). "Combined Activation of Ras and Akt in Neural Progenitors Induces Glioblastoma Formation in Mice," <i>Nat. Genet.</i> 25:55-57.
22.	James, C.D. et al. (1996). "Molecular Genetics and Molecular Biology Advances in Brain Tumors," <i>Curr. Opin. Oncol.</i> 8:188-195.
23.	Khwaja, A. (September 2, 1999). "Akt is More Than Just a Bad Kinase," <i>Nature</i> 401:33-34.
24.	Klagsbrun, M. et al. (October 18, 1991). "A Dual Receptor System is Required for Basic Fibroblast Growth Factor Activity," <i>Cell</i> 67(2):229-231.
25.	Li, D-M. et al. (December 1998). "PTEN/MMAC1/TEP1 Suppresses the Tumorigenicity and Induces G1 Cell Cycle Arrest in Human Glioblastoma Cells," <i>Proc. Natl. Acad. Sci. USA</i> 95:15406-15411.
26.	Li, Y-S. et al. (December 21, 1990). "Cloning and Expression of a Developmentally Regulated Protein That Induces Mitogenic and Neurite Outgrowth Activity," <i>Science</i> 250:1690-1694.
27.	Maehama, T. et al. (April 1999). "PTEN: A Tumour Suppressor That Functions as a Phospholipid Phosphatase," <i>Trends Cell Biol.</i> 9:125-128.
28.	Meremnies, J. et al. (October 5, 1990). "Molecular Cloning of the 18-kDa Growth-Associated Protein of Developing Brain," <i>J. Biol. Chem.</i> 265(28):16721-16724.
29.	Morris, S.W. et al. (March 4, 1994). "Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma," <i>Science</i> 263:1281-1284.
30.	Morris, S.W. et al. (January 20, 1995). "Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma: Sequence Correction," - Erratum <i>Science</i> 267:316-317.
31.	Motegi, A. et al. (2004). "ALK Receptor Tyrosine Kinase Promotes Cell Growth and Neurite Outgrowth," <i>J. Cell Science</i> 117:3319-3329.
32.	Nishikawa, R. et al. (August 1994). "A Mutant Epidermal Growth Factor Receptor Common in Human Glioma Confers Enhanced Tumorigenicity," <i>Proc. Natl. Acad. Sci. USA</i> 91:7727-7731.
33.	Nistér, M. et al. (September 5, 1991). "Differential Expression of Platelet-Derived Growth Factor Receptors in Human Malignant Glioma Cell Lines," <i>J. Biol. Chem.</i> 266(25):16755-16763.
34.	Okada-Ban, M. (March 2000). "Fibroblast Growth Factor-2," <i>Int. J. Biochem. Cell Biol.</i> 32(3):263-267.
35.	O'Rourke, D.M. et al. (April 1997). "Trans Receptor Inhibition of Human Glioblastoma Cells by erbB Family Ectodomains," <i>Proc. Natl. Acad. Sci. USA</i> 94:3250-3255.
36.	Plate, K.H. et al. (October 29, 1992). "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas <i>in vivo</i> ," <i>Nature</i> 359:845-848.
37.	Powers, C.J. et al. (2000). "Fibroblast Growth Factors, Their Receptors and Signaling," <i>Endocr. Relat. Cancer</i> 7(3):165-197.
38.	Schlessinger, J. (October 13, 2000). "Cell Signaling by Receptor Tyrosine Kinases," <i>Cell</i> 103:211-225.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Substitute for form 1449/PTO		Complete if Known	
		Application Number	09/880,097
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	June 14, 2001
		First Named Inventor	Anton WELLSTEIN
		Art Unit	1647
		Examiner Name	C. Nichols
		Attorney Docket Number	544582000200
		Sheet	3

39.	Schulte, A.M. et al. (December 1996). "Human Trophoblast and Choriocarcinoma Expression of the Growth Factor Pleiotrophin Attributable to Germ-Line Insertion of an Endogenous Retrovirus," <i>Proc. Natl. Acad. Sci. USA</i> 93:14759-14764.
40.	Schulte, A.M. et al. (1997). "Pleiotrophin and Related Molecules" Chapter 21 <i>In Tumor Angiogenesis</i> Bicknell, R. et al. eds. Oxford University Press: Oxford, UK 1:273-289.
41.	Schulte, A.M. et al. (July 1998). "Structure and Phylogenetic Analysis of an Endogenous Retrovirus Inserted into the Human Growth Factor Gene Pleiotrophin," <i>J. Virol.</i> 72(7):6065-6072.
42.	Singer, H.S. et al. (1999). "Mitogenesis in Glioblastoma Multiforme Cell Lines: A Role For NGF and its TrkA Receptors," <i>J. Neuro-oncol.</i> 45(1):1-8.
43.	Souttou, B. et al. (August 1, 1997). "Signal Transduction Pathways Involved in the Mitogenic Activity of Pleiotrophin. Implication of Mitogen-Activated Protein Kinase and Phosphoinositide 3-Kinase Pathways," <i>J. Biol. Chem.</i> 272(31):19588-19593.
44.	Souttou, B. et al. (October 7, 1998). "Relationship Between Serum Concentrations of the Growth Factor Pleiotrophin and Pleiotrophin-Positive Tumors," <i>J. Natl. Cancer Inst.</i> 90(19):1468-1473.
45.	Stoica, G.E. et al. (May 18, 2001). "Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin," <i>J. Biol. Chem.</i> 276(20):16772-16779.
46.	Wang, S.I. et al. (October 1, 1997). "Somatic Mutations of <i>PTEN</i> in Glioblastoma Multiforme," <i>Cancer Res.</i> 57:4183-1486.
47.	Weber, D. et al. (March 1999). "Pleiotrophin (PTN) Serves as an Essential Growth Factor in Pancreatic Cancer," <i>Proceedings of the 90th Annual Meeting of the American Association for Cancer Research</i> (April 10 -14, 1999) Philadelphia, PA, 40:732, Abstract No. 4834.
48.	Wellstein, A. et al. (February 5, 1992). "A Heparin-Binding Growth Factor Secreted From Breast Cancer Cells Homologous to a Developmentally Regulated Cytokine," <i>J. Biol. Chem.</i> 267(4):2582-2587.
49.	Wellstein, A. et al. (1999). "Ribozyme Targeting of Angiogenic Molecules" Chapter 25 <i>In Antiangiogenic Agents in Cancer Therapy</i> Teicher, B.A. ed. Humana Press, Inc.: Totowa, NJ. pp. 423-441.
50.	Wen, D. et al. (May 1, 1992). "Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," <i>Cell</i> 69:559-572.
51.	Wen, S. et al. (April 10, 2001). "PTEN Controls Tumor-Induced Angiogenesis," <i>Proc. Natl. Acad. Sci. USA</i> 98(8):4622-4627.
52.	Wu, D. et al. (September 5, 1991). "Characterization and Molecular Cloning of a Putative Binding Protein for Heparin-Binding Growth Factors," <i>J. Biol. Chem.</i> 266(25):16778-16785.
53.	Yeh, H-J. et al. (May 15, 1998). "Upregulation of Pleiotrophin Gene Expression in Developing Microvasculature, Macrophages, and Astrocytes after Acute Ischemic Brain Injury," <i>J. Neurosci.</i> 18(10):3699-3707.
54.	Zhang, N. et al. (July 4, 1997). "Human Breast Cancer Growth Inhibited <i>in Vivo</i> by a Dominant Negative Pleiotrophin Mutant," <i>J. Biol. Chem.</i> 272(27):16733-16736.

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--